Spravato vs Ketamine IV: Comparing Esketamine Nasal Spray to IV Infusions

If you are weighing ketamine-based treatment for depression, one of the first decisions you will face is whether to pursue Spravato (the FDA-approved esketamine nasal spray) or IV ketamine infusions (the off-label but more extensively studied option). They are related but not interchangeable, and the differences go beyond delivery method.

This guide breaks down the pharmacology, evidence, practical considerations, and cost so you can have an informed conversation with your provider.

The Pharmacology: S-Enantiomer vs. Racemic Mixture

Every ketamine molecule exists in one of two mirror-image forms: S-ketamine (esketamine) and R-ketamine (arketamine). Standard IV ketamine is racemic, meaning it contains a 50/50 mix of both forms. Spravato contains only esketamine.

This matters because the two enantiomers have different pharmacological properties:

• Esketamine (S-ketamine) binds to NMDA receptors with approximately 3 to 4 times greater affinity than R-ketamine. It is more potent as an anesthetic and produces stronger dissociative effects at equivalent doses.
• Arketamine (R-ketamine) has weaker NMDA binding but appears to have its own antidepressant mechanisms. Animal studies published in Pharmacology Biochemistry and Behavior (2017) found that R-ketamine produced longer-lasting antidepressant effects than S-ketamine in rodent models, possibly through different downstream pathways involving AMPA receptors and BDNF signaling.

The implication is that racemic ketamine may offer something that esketamine alone does not: the combined activity of both enantiomers, each contributing different mechanisms of antidepressant action. Some researchers, including Kenji Hashimoto at Chiba University, have argued that R-ketamine may actually be the more important enantiomer for treating depression, with fewer side effects than S-ketamine. This hypothesis is still being tested in human trials (arketamine is currently in Phase II clinical trials).

Efficacy: What the Trials Show

IV Ketamine Evidence

IV racemic ketamine has been studied in dozens of randomized controlled trials since the landmark Zarate study in 2006. Key findings:

• Response rates of 50 to 70% in treatment-resistant depression (TRD), typically within 24 hours of a single infusion.
• The Murrough 2013 trial (the largest at the time) showed a 64% response rate vs. 28% for active placebo (midazolam) at 24 hours.
• Rapid reduction in suicidal ideation, often within hours, as documented in the Wilkinson 2018 meta-analysis.
• Effects of a single infusion typically last 1 to 2 weeks; repeated infusions (6 over 2 to 3 weeks) produce more durable responses.
• Most trials are independently funded by academic institutions or the NIH.

Spravato Evidence

Spravato’s FDA approval was based on several Phase III trials funded by Janssen (Johnson & Johnson’s pharmaceutical division):

• TRANSFORM-1, TRANSFORM-2, and TRANSFORM-3 were the pivotal trials. Of these, only TRANSFORM-2 met its primary endpoint, showing a statistically significant improvement in depression scores (MADRS) compared to placebo nasal spray plus a new oral antidepressant. TRANSFORM-1 and TRANSFORM-3 did not reach statistical significance on their primary endpoints.
• The SUSTAIN-1 long-term maintenance trial showed that patients who continued Spravato had lower relapse rates than those switched to placebo.
• Spravato also received FDA approval in 2020 for major depressive disorder with acute suicidal ideation or behavior, based on the ASPIRE I and ASPIRE II trials, which showed rapid (within 24 hours) reduction in depressive symptoms compared to placebo.

The mixed results of the pivotal trials have been a source of debate. Critics point out that two of three Phase III trials failed their primary endpoint, and that the magnitude of benefit in TRANSFORM-2 was modest compared to what is typically reported in IV ketamine trials. Supporters counter that the trial design (adding Spravato vs. placebo on top of a new oral antidepressant) made it harder to show separation, since both groups were starting a new medication.

Head-to-Head Comparisons

Direct comparisons between IV racemic ketamine and intranasal esketamine are limited but growing. A 2021 non-inferiority trial published in the New England Journal of Medicine (the ELEKT-D trial, also known as the PCORnet study) compared IV ketamine to Spravato in patients with TRD and found that IV ketamine was at least as effective as Spravato, with some measures favoring IV ketamine. A 2022 meta-analysis in the Journal of Affective Disorders reached a similar conclusion: IV racemic ketamine showed numerically higher response rates than intranasal esketamine, though the difference was not always statistically significant due to heterogeneity across studies.

The REMS Program: What It Means in Practice

Because of concerns about misuse, sedation, and dissociation, the FDA requires Spravato to be distributed under a Risk Evaluation and Mitigation Strategy (REMS). In practical terms, this means:

• Spravato can only be administered at a certified healthcare facility enrolled in the REMS program.
• Patients self-administer the nasal spray under the direct supervision of a healthcare provider.
• You must be monitored in the clinic for at least 2 hours after each dose.
• You cannot take Spravato home, and you cannot drive or operate machinery until the next day.
• The prescribing provider, the pharmacy, and the healthcare facility all must be enrolled in the REMS.

IV ketamine has no REMS requirement. However, responsible clinics provide similar levels of monitoring (vital signs, supervised recovery period, no driving on treatment day).

Side Effects Comparison

Some patients tolerate one form better than the other. Patients who are needle-averse may prefer the nasal spray. Patients who experience significant nasal discomfort or who have sinus issues may prefer IV administration.

Insurance Coverage and Cost

This is often the deciding factor for patients. The cost structures are very different:

Spravato

• List price: $590 to $885 per session (depending on dose: 56 mg or 84 mg)
• Insurance: Many commercial plans and Medicare Part D cover Spravato with prior authorization. Prior auth typically requires documented failure of at least 2 antidepressants.
• Patient copay: Varies widely, from $0 to $250+ per session depending on your plan. Janssen offers a savings program (CarePath) that can reduce costs for commercially insured patients.
• First-year cost with insurance: $1,000 to $5,000+ (estimated, highly variable by plan)

IV Ketamine

• Per session: $400 to $800
• Initial series (6 infusions): $2,400 to $4,800
• Monthly maintenance: $400 to $800 per infusion
• Insurance: Rarely covered; off-label use. Some patients have success with HSA/FSA funds.
• First-year cost: $4,000 to $10,000+

Convenience and Practical Considerations

Which One Is Right for You?

There is no single right answer. Here are some scenarios to consider:

• Insurance covers Spravato and cost is your top concern: Start with Spravato. The financial burden will likely be lower, and if it works, you have a sustainable long-term option.
• You are paying out of pocket: IV ketamine is often the better value per session, has a larger independent evidence base, and gives your clinician more flexibility with dosing.
• You tried Spravato without adequate response: IV racemic ketamine is worth trying. The R-enantiomer component may produce a different or better response for some individuals.
• You are needle-averse: Spravato avoids the IV line entirely, which matters for comfort and compliance.
• You have severe or acute suicidal ideation: Both have evidence, but IV ketamine offers the most rapid onset and the most precise dose control in urgent situations. Discuss with your psychiatrist.

Whatever you choose, work with a provider experienced in ketamine-based treatments who can monitor your response and adjust the approach as needed. For more on ketamine’s role in depression treatment, see our full guide on ketamine for depression.

The Bottom Line

Spravato and IV ketamine are both legitimate treatments for treatment-resistant depression, and both work through NMDA receptor blockade. The choice between them often comes down to insurance coverage, cost tolerance, convenience, and individual response. Spravato has the regulatory advantage and insurance access. IV ketamine has the deeper research base and the potential advantage of racemic pharmacology. Some patients end up trying both before finding what works best for them.

Neither is a magic bullet. Both work best as part of a broader treatment plan that includes therapy, lifestyle modification, and ongoing psychiatric care.

Related Reading

• Ketamine Therapy: The Complete Guide
• Ketamine for Depression: Evidence, Protocols, and What to Expect
• Ketamine Therapy Cost Breakdown
• Is Ketamine Therapy Covered by Insurance?

Frequently Asked Questions

What is the difference between Spravato and IV ketamine?

Spravato is an FDA-approved nasal spray that contains only the S-enantiomer of ketamine (esketamine), while IV ketamine infusions use racemic ketamine, a 50/50 mix of both the S- and R-enantiomers. Spravato is self-administered as a nasal spray under clinical supervision, whereas IV ketamine is delivered as an intravenous infusion. IV ketamine is used off-label for depression, while Spravato carries FDA approval.

Is Spravato FDA approved and is IV ketamine legal?

Spravato is FDA approved for treatment-resistant depression and received FDA approval in 2020 for major depressive disorder with acute suicidal ideation or behavior. IV ketamine remains off-label for depression, meaning it is legal but not FDA approved for this specific use.

How much do Spravato and IV ketamine cost, and does insurance cover them?

Spravato has a list price of $590 to $885 per session, with a first-year cost of roughly $1,000 to $5,000 or more when insurance is applied; many commercial plans and Medicare Part D offer coverage with prior authorization. IV ketamine runs $400 to $800 per session, or $2,400 to $4,800 for an initial series of six infusions, and a first-year cost of $4,000 to $10,000 or more. IV ketamine is rarely covered because of its off-label use.

How well do they work for depression?

IV ketamine shows response rates of 50 to 70% in treatment-resistant depression, typically within 24 hours, and one trial (Murrough 2013) reported a 64% response rate versus 28% for active placebo. For Spravato, only the TRANSFORM-2 trial met its primary endpoint while TRANSFORM-1 and TRANSFORM-3 did not reach statistical significance, meaning two of three Phase III trials failed their primary endpoint. A 2021 non-inferiority trial found IV ketamine was at least as effective as Spravato.

What are the side effects and how long is monitoring?

Both can cause dissociation, nausea, elevated blood pressure, headache, and dizziness or sedation. Nausea occurs in about 10 to 20% of IV ketamine sessions versus 20 to 30% for Spravato, and Spravato can also cause nasal discomfort and potentially more intense dissociation due to its higher NMDA affinity. Spravato requires at least 2 hours of monitoring per REMS requirements, while IV ketamine typically involves 30 to 60 minutes of post-infusion monitoring.

What does a typical treatment schedule look like?

IV ketamine typically starts at 3 times per week for 2 weeks, then moves to monthly or as-needed maintenance. Spravato typically starts at 2 times per week for 4 weeks, then transitions to weekly or biweekly and later as-needed dosing. The article stresses that neither is a magic bullet and both work best as part of a broader treatment plan.